ClinicalTrials.gg
Active, not recruitingNCT03892655LB1802Updated Dec 24, 2025

Real World Study of Biosimilar Trastuzumab in Her2 Positive Breast Cancer

An observational study in Breast Cancer, sponsored by Libbs Farmacêutica LTDA. Active, not recruiting at 22 sites in Brazil. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-24.

Sponsored by Libbs Farmacêutica LTDA · Observational

How we know · 2 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
170
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 351 studies in Breast Neoplasms with a site in Brazil — 52 open to participants now, 111 under way, 62 of them phase 3. Breast Neoplasms · Brazil.

Enrollment
25th of 40
170 · median 251
Started
2019
with 17 others
Observational
40 of 351
3 open now
Primary completion
2022-12
later than 5 of 110 live
Registered
197th of 351
by date

Among the 351 studies in Breast Neoplasms with a site in Brazil, this one is the 25th largest by enrollment of the 40 observational ones that give a count, is one of 18 that started in 2019, is one of 40 observational ones, reaches primary completion later than 5 of the 110 other live ones, and was the 197th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

52 of the 351 studies in Breast Neoplasms with a site in Brazil are open now. Recruiting first, the newest first:

47 more — sign in →

All 52 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 351 studies in Breast Neoplasms with a site in Brazil, or all of them as a file.
02

Study summary

Zedora registration was based on studies of women with metastatic breast cancer, but its approval includes adjuvant treatment. Thus, prospective data of drug use in localized disease are lacking, as well as are real-world safety and efficacy data, taking into consideration comorbidities and compliance difficulties.

This will be an observational study of patients receiving adjuvant Zedora at several Brazilian institutions for the purpose of describing its efficacy and safety.

Read the detailed description

An observational, multicenter, prospective, real-world study at Brazilian institutions.

Adult patients with early HER2+ breast cancer receiving adjuvant biosimilar trastuzumab (Zedora) at the participating sites after the start of the study and meeting the eligibility criteria will be invited to participate. Demographics, comorbidities, disease history, extent of exposure to biosimilar trastuzumab (Zedora), adverse events and LVEF values will be collected.

Data collection will be performed using a case report form (CRF) specifically designed for the study.

Study Treatment:

Biosimilar trastuzumab (Zedora) must be prescribed at the dosage described in the product label.

Treatment duration will be 12 months for patients starting upfront with biosimilar trastuzumab (Zedora). Patients switching at any time to biosimilar trastuzumab (Zedora) after a period of adjuvant or neoadjuvant Herceptin® use will also be included in the overall analysis and subsequently assessed in a subgroup analysis.

Sample Size:

Number of patients = 170 Given the inexistence of a specific hypothesis to be tested, the statistical analysis will be basically descriptive.

Sample size is based on the two-sided 95% confidence interval (95% CI) for the invasive disease relapse-free survival rate.

The table below shows the 95% CIs for different rates in a sample of 170 patients, with an interval size ranging between 9% and 15%.

Based on literature, a 3-year relapse-free survival between 88 and 96% is expected. According to the table above, a sample of 170 patients allows assessing this endpoint with +/- 6.0% accuracy.

Study duration:

The estimated time for patient enrollment in the study is one year and may be extended in case the sample size is not reached in this period. Biosimilar trastuzumab (Zedora) must be prescribed according to the product label and treatment duration will be up to one year. The patient will be maintained in the study for 5 years (from start of treatment), unless there is tumor recurrence (local or distant).

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • breast carcinoma
  • receptors 2 (HER2)
  • biosimilar
  • trastuzumab
  • Zedora
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult female patients with diagnosis of early stage I to III HER2+ breast cancer confirmed by histopathology test, immunohistochemistry test and FISH, where required, according to local guidelines, and who have started biosimilar trastuzumab (Zedora) as neoadjuvant or adjuvant therapy according to the product label will be eligible for the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • female patients aged 18 years and over
  • diagnosis of early stage I to III breast cancer confirmed by histopathology test according to local guidelines.
  • human epidermal growth factor receptor 2 ()-positive tumor by immunohistochemistry or FISH (Fluorescence In Situ Hybridization), as per the 2018 ASCO assessment guideline [J Clin Oncol 36:2105, 2018].
  • use of at least one dose of biosimilar trastuzumab (Zedora) as therapy, regardless of previous neoadjuvant trastuzumab or Zedora use or the type of chemotherapy combined with the antibody.
  • Signing of the form (ICF).

Exclusion criteria

Exclusion Criteria:

  • use of biosimilar trastuzumab (Zedora) differently from the provisions in the label.
  • patients enrolled in and followed up by Programa Vida Plena [Full Life Program].
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
170 participants (actual)
Target follow-up
5 Years
Patient registry
Yes

This study also gives TrastuzumabStudies of TrastuzumabTrastuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Efficacy endpoints: Invasive disease relapse-free survival rate

    Invasive disease relapse-free survival rate

    Time frame: 18 months

  2. Efficacy endpoints: Invasive disease relapse-free survival rate

    Invasive disease relapse-free survival rate

    Time frame: 24 months

  3. Efficacy endpoints: Invasive disease relapse-free survival rate

    Invasive disease relapse-free survival rate

    Time frame: 30 months

  4. Efficacy endpoints: Invasive disease relapse-free survival rate

    Invasive disease relapse-free survival rate

    Time frame: 36 months

  5. Efficacy endpoints: Invasive disease relapse-free survival after curative-intent surgery

    Invasive disease relapse-free survival after curative-intent surgery

    Time frame: 5 years

  6. Efficacy endpoints: Overall survival after curative intent surgery

    Overall survival after curative intent surgery

    Time frame: 5 years

  7. Safety endpoints: Incidence of Related Adverse Events

    Incidence of Related Adverse Events

    Time frame: 5 years

  8. Safety endpoints: Total cycles per patient

    Total cycles per patient

    Time frame: 5 years

  9. Safety endpoints: Incidence of dose interruption

    Incidence of dose interruption

    Time frame: 5 years

07

Study locations

22 sites
  • William Hiromi Fuzita
    Manaus, Amazonas 69057205, Brazil
  • Márcia Cristina Colares Régis de Araújo
    Fortaleza, Ceará 60135285, Brazil
  • Raphael Luzorio Fernandes
    Cachoeiro de Itapemirim, Espírito Santo, Brazil
  • Sabina Bandeira Aleixo
    Cachoeiro de Itapemirim, Espírito Santo, Brazil
  • Daniel Fontes Santos de Teive e Argolo
    Salvador, Estado de Bahia 41810570, Brazil
  • Ruffo de Freitas Junior
    Goiânia, Goiás, Brazil
  • Cristina de Deus Anjos Tavares Sampaio
    Campo Grande, Mato Grosso, Brazil
  • Luis Eduardo Rosa Zucca
    Três Lagoas, Mato Grosso do Sul, Brazil
  • Micheline Campos Rezende
    Muriaé, Minas Gerais, Brazil
  • Karina Costa Maia Vianna
    Curitiba, Paraná, Brazil
  • Sérgio Lunardon Padilha
    Curitiba, Paraná, Brazil
  • Sâmio Pimentel Ferreira
    Belém, Pará 66035265, Brazil
  • Cláudio Rocha
    Teresina, Piauí 64049-200, Brazil
  • Andrea Juliana Pereira de Santana Gomes
    Natal, Rio Grande do Norte 59075740, Brazil
  • Tomas Reinert
    Caxias do Sul, Rio Grande do Sul, Brazil
  • Rafaela Kirchner Piccoli
    Ijuí, Rio Grande do Sul, Brazil
  • Mateus Bongers Alessandretti
    Porto Alegre, Rio Grande do Sul, Brazil
  • Charles Alain Cordova Pinto
    Lages, Santa Catarina, Brazil
  • Daniel Grabarz
    Mogi das Cruzes, São Paulo 08730500, Brazil
  • Monique Celeste Tavares
    São Paulo, São Paulo 01509-900, Brazil
  • Kaique Almeida
    São Paulo, São Paulo, Brazil
  • Mariana Scaranti
    São Paulo, São Paulo, Brazil
08

References and documents

Publications

  • Gagliato D, Reinert T, Rocha C, Tavares M, Pimentel S, Fuzita W, Araujo M, Matias D, Aleixo S, Franca B, Magaton E, Brito N, Cardoso AC, Castilho V. Real-World Study of Adjuvant Biosimilar Trastuzumab-dkst for HER2-Positive Breast Cancer Treatment in a Brazilian Population. Oncol Ther. 2024 Sep;12(3):437-449. doi: 10.1007/s40487-024-00284-5. Epub 2024 Jun 5. PubMed 38836997 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Dec 2022, 38 months.

Of 189 industry-sponsored observational studies under Breast Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 70. This study's 38 months is below that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2019
First posted
Mar 27, 2019
StartActual
Oct 7, 2019
Primary completionActual
Dec 30, 2022
CompletionEst.
Jul 2028
Last update
Dec 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03892655
Lead sponsor
Libbs Farmacêutica LTDA
Responsible party
Sponsor
First posted
Mar 27, 2019
Start date
Oct 7, 2019
Primary completion
Dec 30, 2022
Completion
Jul 2028 (estimated)
Last update
Dec 24, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion